ArticleBrazilian journal of otorhinolaryngology
Dual-mechanism therapy for chronic rhinosinusitis via siRNA targeting of bacterial 16S rRNA and disruption of CFTR-pathogen interactions.
Article in Brazilian journal of otorhinolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OBJECTIVE(S): This study aimed to develop a dual-mechanism therapeutic strategy for Chronic Rhinosinusitis (CRS) associated with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutations. Specifically, we sought to (1) Design siRNAs targeting conserved regions of the bacterial 16S rRNA gene to reduce pathogen viability and (2) Investigate the interaction between mutant CFTR (PDB: 1XMJ) and a bacterial ribosomal component (PDB: 8SR6) to identify novel inhibitory pathways.
methodsComputational algorithms were used to design siRNAs complementary to 10 target sites on the 16S rRNA gene. Molecular docking and dynamics simulations analyzed the interaction between mutant CFTR (1XMJ) and the 16S rRNA-associated protein (8SR6). In vitro validation included siRNA transfection into Pseudomonas aeruginosa biofilms and Surface Plasmon Resonance (SPR) assays to quantify 1XMJ-8SR6 binding. Human sinonasal epithelial cells with CFTR mutations were used to model CRS pathophysiology.
resultsMultiple siRNA candidates targeting conserved regions of the 16S rRNA gene were identified, exhibiting favorable GC content and predicted high silencing efficacy. Three siRNAs demonstrated >70% silencing efficacy against 16S rRNA, reducing bacterial viability by 60% in biofilms. Docking simulations revealed strong binding affinity (KD = 2.3 nM) between mutant CFTR (1XMJ) and 8SR6, localized to a hotspot region critical for bacterial adhesion.
conclusionThe dual targeting of bacterial 16S rRNA via siRNA and disruption of CFTR-pathogen protein interactions presents a promising strategy for CRS treatment, particularly in CFTR-mutation-associated cases. This approach could mitigate antibiotic resistance by directly silencing bacterial genes while modulating host-pathogen crosstalk. Further in vivo validation is warranted to advance translational potential. LEVEL OF EVIDENCE: Level III (Experimental study with laboratory validation).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.